RecruitingNot ApplicableNCT06929533

Pharmacogenomics-Supported Psychotropic Prescribing Trial

Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba


Sponsor

University of Manitoba

Enrollment

200 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether using genetic testing (pharmacogenomics) to guide which psychiatric medications a doctor prescribes leads to better outcomes for patients. A saliva sample is used to identify genetic variations that affect how a person processes certain medications. **You may be eligible if...** - You are 18 years or older - Your doctor has decided you need to start, change, or adjust a psychiatric medication (such as an antidepressant or antipsychotic) - Your treating doctor believes genetic testing would help guide your prescription **You may NOT be eligible if...** - You refuse to provide a saliva sample for genetic testing - You have had a liver or bone marrow transplant - You already have pharmacogenomics (genetic drug response) test results available - You do not have a personal health identification number Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPharmacogenetic Testing

Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.


Locations(2)

Shared Health Facilities

Winnipeg, Manitoba, Canada

University of Manitoba College of Pharmacy

Winnipeg, Manitoba, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06929533


Related Trials